Latin America Drug Delivery Devices Market size is expected to grow at a CAGR of 9.8% during the forecast period 2022 to 2028. The Latin America market provides a detailed overview and that can be segmented by product type, by route of administration, by formulation, by application, and by distribution channel. By product type, the Latin America drug delivery devices market has been segmented into infusion Pumps, Metered Dose Inhalers, Nebulizers, Syringes, Ocular Inserts, Nasal Sprays, Implantable Drug Delivery Devices, Transdermal Patches, Trans-Mucosal Drug Delivery Devices, and Others. The infusion Pumps segment is likely to be the largest and fastest-growing segment in terms of type in 2021 and is expected to maintain the trend in the forecasted years. Based on route of administration, the Latin America drug delivery devices market is segmented into Oral, Parenteral, Transdermal, Trans-Mucosal, Inhalation, Ocular, and Others. Among these, the Oral segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on formulation, the Latin America drug delivery devices market is segmented into Solid, Liquid, Semi-Solid. The Liquid segment accounts for the largest share in 2021. Hosted segment is the second-largest share during the forecast period 2022-2028. Based on the application, the segment has been segregated into Diabetes, Oncology, Autoimmune Disorders, Neurological Disorders, Gastrointestinal Disorders, Respiratory Disorders, and Others. The Diabetes segment is expected to dominate other segments in the Latin America drug delivery devices market. The Oncology segment is expected to witness the highest CAGR during the forecast period according to precision business insights. Based on distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others. The Hospital Pharmacies segment accounts for the largest share in 2021 and is anticipated to register a significant CAGR in the upcoming years.
In Oct 2022, Merck KGaA extended its collaboration with Biocorp to develop a version of a Bluetooth enabled clip-on device that is specific to one of its drug delivery devices.
In Oct 2022, Eisai started work on $69M injectable drug delivery facility.